Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) PT at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $94.63.

A number of equities analysts recently issued reports on the company. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday. They issued an “equal weight” rating and a $95.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $98.65 on Tuesday. LeMaitre Vascular has a 1 year low of $59.87 and a 1 year high of $109.58. The stock has a market cap of $2.22 billion, a P/E ratio of 53.91, a P/E/G ratio of 2.19 and a beta of 0.96. The stock has a 50-day simple moving average of $95.94 and a 200-day simple moving average of $93.61.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in LMAT. Smartleaf Asset Management LLC grew its stake in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its position in LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 117 shares during the last quarter. NBC Securities Inc. increased its stake in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the period. GAMMA Investing LLC raised its position in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 188 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 410 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.